

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/551,789
				Filing Date	07-05-2006
				First Named Inventor	Michael Thomas Clandinin
				Art Unit	1623
				Examiner Name	Eric Olson
Sheet	2	of	21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ALONSO et al., "Dissociation of the Effects of the Antitumour Ether Lipid ET-18-OCH ₃ on Cytosolic Calcium and on Apoptosis", Brit. J. Pharmacol. 121 (1997) 1364-1368.	
	2	ANDERSON et al., "Essential Fatty Acid Deficiency and Renewal of Rod Outer Segments in the Albino Rat", Invest Ophthalmol. 15, 232-236 (1976).	
	3	ANDERSON, "The Caveolae Membrane System", Annual Review of Biochemistry; 1998;67:199-225.	
	4	ANDERSSON et al., "Rates of Cholesterol, Ubiquinone, Dolichol and Doclichyl-P Biosynthesis in Rat Brain Slices", FEBS Lett 1990;269:15-8.	
	5	ASOU et al., "Changes in Ganglioside Composition and Morphological Features During the Development of Cultured Astrocytes From Rat Brain", Neurosci. Res. 6 (1989) 369-375.	
	6	AYDIN et al., "Age-Related Changes in GM1, GD1a, GT1b Components of Gangliosides in Wistar Albino Rats", Cell Biochem Funct 2000;18:41-5.	
	7	BARBOUR et al., "Glycolipid Depletion Using a Ceramide Analogue (PDMP) Alters Growth, Adhesion, and Membrane Lipid Organization in...", J. Cell. Physiol. 150, 610-619 (1992).	
	8	BASAVARAJAPPA et al., "Activation of Arachidonic Acid-Specific Phospholipase A2 in Human Neuroblastoma Cells after ...", Clin. Exp. Res. 21 (1997) 1199-1203.	
	9	BASTIAANSE et al., "The Effect of Membrane Cholesterol Content on Ion Transport Processes in Plasma Membranes", Cardiovasc Res 1997;33:272-83.	
	10	BAULDRY et al., "Phospholipase A2 Activation in Human Neutrophils", J. Biol. Chem. 263 (1988) 16787-16795.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 3	of 21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	BAULDRY et al., "Differential Actions of Diacyl- and Alkylacylglycerols in Priming Phospholipase A2, 5-Lipoxygenase ..., Biochim. Biophys. Acta 1084 (1991) 178-184.	
	12	BAVARI et al., "Lipid Raft Microdomains: A Gateway for Compartmentalized Trafficking of Ebola and Marburg Viruses", J Exp Med 2002;195(5):593-602.	
	13	BELOSEVIC et al., "Giardia muris: Correlation Between Oral Dosage, Course of Infection, and Trophozoite Distribution in the Mouse..", 1983. Exp. Parasitol. 56:93-100	
	14	BERNETT et al., "Determination of Serum Phospholipid Metabolic Profiles by High-Performance Liquid Chromatography", J. Liq. Chromatogr. 8 (1985) 1573-1591.	
	15	BERGER et al., "Nutritional Implications of Replacing Bovine Milk Fat With Vegetable Oil in Infant Formulas", J. Pediatr. Gastroenterol. Nutr. 30 (2000) 115-130.	
	16	BIRCH et al., "Visual Acuity and the Essentiality of Docosahexaenoic Acid and Arachidonic Acid in the Diet of Term Infants", Pediatr. Res. 44, 201-209 (1998).	
	17	BITTMAN et al., "Influence of Cholesterol on Bilayers of Ester-and Ether-Linked Phospholipids", Biochim. Biophys. Acta 772 (1984) 117-126.	
	18	BLANK et al., "Meats and Fish Consumed in the American Diet Contain Substantial Amounts of Ether-Linked Phospholipids", J. Nutr. 122 (1992) 1656-1661.	
	19	BOUHOURS et al., "Developmental Changes of Hematoside of Rat Small Intestine", J. Biol. Chem. 258 (1983) 299-304.	
	20	BROWN et al., "Sorting of GPI-Anchored Proteins to Glycolipid-Enriched Membrane Subdomains During Transport to the Apical Cell Surface", 1992. Cell. 68:533-544.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet	4	of	21
		Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	BROWN et al., "Functions of Lipid Rafts in Biological Membranes", Annu Rev Cell Dev Biol 1998;14:111-36.	
	22	BURET et al., "Growth, Activities of Enzymes in the Small Intestine, and Ultrastructure of Microvillous Border in Gerbils ..", 1991. Parasitol Res. 77:109-114.	
	23	BYRNE et al., "Ganglioside-Induced Neuritogenesis: Verification That Ganglioside Are the Active Agents, and Comparison of Molecular Species", J. Neurochem. 41 (1983) 1214-122	
	24	Carlson, "N-Acetylneuraminic Acid Concentrations in Human Milk Oligosaccharides and Glycoproteins During Lactation", Am J Clin Nutr 1985;41:720-6.	
	25	CARLSON et al., "Visual Acuity and Fatty Acid Status of Term Infants Fed Human Milk and Formulas With and Without Docosahexaenoate and ..", Pediatr. Res. 39, 882-888 (1996).	
	26	CARRIE et al., "Docosahexaenoic Acid-Rich Phospholipid Supplementation", Nutr. Neurosci. 5, 43-52 (2002).	
	27	CHEN et al., "Sphingomyelin Content of Intestinal Cell Membranes Regulates Cholesterol Absorption", Biochem J 1992;286 (Pt 3):771-777.	
	28	CHRISTIANSEN et al., "Microvillus Membrane Vesicles From Pig Small Intestine", Biochim. Biophys. Acta 647 (1981) 188-195.	
	29	CLANDININ et al., "Effects of Methionine Supplementation on the Incidence of Dietary Fat Induced Myocardial Lesions in the Rat", J. Nutr. 110 (1980) 1197-203.	
	30	CLANDININ et al., "Dietary Fat: Exogenous Determination of Membrane Structure and Cell Function", FASEB J 1991;5:2761-9.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 5 of 21	Application Number	10/551,789
	Filing Date	07-05-2006
	First Named Inventor	Michael Thomas Clandinin
	Art Unit	1623
	Examiner Name	Eric Olson
	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	31	DANIELS et al., "Disaccharidase Activity in Male and Female C57BL/6 Mice Infected with Giardia Muris", 1995. Parasitol Res. 81:143-147.	
	32	DANIELSEN et al., "A Transferrin-Like GPI-linked Iron-Binding Protein in Detergent-Insoluble Noncaveolar Microdomains at the Apical ..Cells", J Cell Biol 1995; 131(4):939-50.	
	33	DANIELSEN, "Involvement of Detergent-Insoluble Complexes in the Intracellular Transport of Intestinal Brush Border Enzymes", Biochemistry 1995; 34(5):1596-1605.	
	34	DANIOTTI et al., "GD3 Ganglioside Is Prevalent in Fully Differentiated Neurons From Rat Retina", J. Neurosci. Res. 26, 436-446 (1990).	
	35	DANIOTTI et al., "Regulation of Ganglioside Composition and Synthesis is Different in Developing Chick Retinal Pigment Epithelium...", J. Neurochem. 62 (1994) 1131-1136.	
	36	DE MARIA et al., "Requirement for GD3 Ganglioside in CD95- and Ceramide-Induced Apoptosis", Science 1997;277:1652-5.	
	37	DIAMOND et al., "A New Medium for the Axenic Cultivation of Entamoeba Histolytica and Other Entamoeba", 1978. Trans. R. Soc. Trop. Med. Hyg. 72:431-432.	
	38	DIOMEDE et al., "Role of Cell Cholesterol in Modulating Antineoplastic Ether Lipid Uptake, Membrane Effects and Cytotoxicity", Int. J. Cancer 46 (1990) 341-346.	
	39	DIOMEDE et al., "Fluorescence Polarization Changes with Gestational Age in Amniotic Fluid of Rabbit and Guinea Pig", Exp. Lung. Res. 16 (1990) 507-519.	
	40	DIOMEDE et al., "Increased Ether Lipid Cytotoxicity by Reducing Membrane Cholesterol Content", Int. J. Cancer 49 (1991) 409-413.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 6	of 21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	41	DIOMEDE et al., "Induction of Apoptosis in Human Leukemic Cells by the Ether Lipid 1-Octadecyl-2-Methyl-Rac-Glycero-3-Phosphocholine", Int. J. Cancer 53 (1993) 124-130.	
	42	DREYFUS et al., Simplified Ganglioside Composition of Photoreceptors Compared to Other Retinal Neurons", Invest Ophthalmol. Vis. Sci. 37, 574-585 (1996).	
	43	DREYFUS et al., "Ganglioside and Neurotrophic Growth Factor Interactions in Retinal Neuronal and Glial Cells", Indian J. Biochem. Biophys. 34, 90-96 (1997).	
	44	FALDELLA et al., "Visual Evoked Potentials and Dietary Long Chain Polyunsaturated Fatty Acids in Preterm Infants", Arch. Dis. Child. 75, F108-F112 (1996).	
	45	FANTINI. "Synthetic Soluble Analogs of Glycolipids for Studies of Virus-Glycolipid Interactions", Sphingolipid Metabolism and Cell Signaling, Pt A 2000;311:626-38.	
	46	FAROOQUI et al., "Glycerophospholipids in Brain: Their Metabolism, Incorporation into Membranes, Functions..", Chem. Phys. Lipids 106 (2000) 1-29.	
	47	FARTHING. "Giardiasis", 1996. Gastro. Clin. North Am. 25:493-515.	
	48	FIELDING et al., "Caveolin mRNA Levels are Up-Regulated by Free Cholesterol and Down-Regulated by ...", Proc Natl Acad Sci U S A 1997;94(8):3753-8.	
	49	FLICKINGER et al., "Localization of the Platelet-Activating Factor Receptor to Rat Pancreatic Microvascular Endothelial Cells", Am. J. Pathol. 1999;154(5):1353-8.	
	50	FOLCH et al., "A Simple Method for the Isolation and Purification of Total Lipides From Animal Tissues", 1957. J. Biol. Chem. 226:497-509.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 7	of 21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	51	FONTAINE et al., "Changes in Ganglioside Composition of Photoreceptors During Postnatal Maturation of the Rat Retina", Glycobiology 8, 183-190 (1998).	
	52	FORSTNER et al., "Plasma Membrane and Mucosal Glycosphingolipids in the Rat Intestine", Biochim. Biophys. Acta 306 (1973) 446-459.	
	53	FUJITO et al., "Promotion of Sprouting and Synaptogenesis of Cerebrofugal Fibers by Ganglioside Application in the Red Nucleus", Neurosci. Res. 2, 407-411 (1985).	
	54	FURUCHI et al., "Cholesterol Depletion of Caveolae Causes Hyperactivation of Extracellular Signal-related Kinase (ERK)", J Biol Chem 1998;273:21099-21104.	
	55	GATT et al., "Sphingomyelin Suppresses the Binding and Utilization of Low Density Lipoproteins by Skin Fibroblasts", J Biol Chem 1980;255:3371-6.	
	56	GIBSON et al., "Giardia Lamblia: Incorporation of Free and Conjugated Fatty Acids Into Glycerol-Based Phospholipids", 1999. Exp. Parasitol. 92:1-11.	
	57	GILLIN. "Giardia Lamblia: The Role of Conjugated and Unconjugated Bile Salts in Killing by Human Milk", 1987. Exp. Parasitol. 63:74-83	
	58	GILLIN et al., "Cholate-Dependent Killing of Giardia Lamblia by Human Milk", 1985 Infect. Immun. 47:619-622.	
	59	GIUSTO et al., "Lipid Metabolism in Photoreceptor Membranes: Regulation and Mechanisms", Neurochem. Res. 22, 445-453 (1997).	
	60	GILLON et al., "Features of Small Intestinal Pathology (Epithelial Cell Kinetics, Intraepithelial Lymphocytes, Disaccharidases) in a ...", 1982. Gut. 23:498-506.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 8	of 21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	61	GLICKMAN et al., "Characterizations, Distribution and Biosynthesis of the Major Ganglioside of Rat Intestinal Mucosa", Biochim. Biophys. Acta 424 (1976) 17-25.	
	62	GUELMAN et al., "GM1 Ganglioside Treatment Protects Against Long-Term Neurotoxic Effects of Neonatal X-irradiation on Cerebellar ..", Brain Res. 858 (2000) 303-311.	
	63	HAILSTONES et al., "Regulation of Caveolin and Caveolae by Cholesterol in MDCK Cells", J Lipid Res 1998;39(2):369-79.	
	64	HAKOMORI et al., "Variation in Components and Function of Glycosignaling Domain, and Factors Affecting Them", Glycobiology 2000;10(10):1086-7.	
	65	HARA et al., "Occurrence of Sulfatide as a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins", J. Biochem. 102 (1987) 83-92.	
	66	HO et al., "Development and Regulation of Rhodopsin Kinase in Rat Pineal and Retina", J. Neurochem. 46, 1176-1179 (1986).	
	67	HOFFMAN et al., "Visual Function in Breast-Fed Term Infants Weaned to Formula With or Without Long-Chain Polyunsaturates at 4 to 6 Months", J. Pediatr. 142, 669-677 (2003).	
	68	HOGYES et al., "Neuroprotective Effect of Developmental Docosahexaenoic Acid Supplement Against Excitotoxic Brain..", Neuroscience 119 (2003) 999-1012.	
	69	HOLGERSSON et al., "Human Large Intestine Glycolipids", Biochimie 1988;70:1565-74.	
	70	HOLMGREN et al., "Comparison of Receptors for Cholera and Escherichia coli Enterotoxins in Human Intestine", 1985. Gastroenterology. 89:27-35.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
Examiner Name	Eric Olson		
Sheet 9	of 21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	71	HOLUB et al., "Nutritional Regulation of Cellular Phosphatidylinositol", in: P.M. Conn and A.R. Means (Eds), Methods in Enzymology, Academic Press, New York, 1987, pp. 234-244	
	72	HONMA et al., "Induction of Differentiation of Cultured Human and Mouse Myeloid Leukemia Cells by Alkyl-Lysophospholipids", Cancer Res. 41 (1981) 3211-3216.	
	73	HORROCKS, "Ether lipids", in: F. Snyder (Ed.), Content, Composition, and Metabolism of Mammalian and Avian Lipids, Academic Press, New York, 1972, pp. 177-272.	
	74	HUSTER, et al., "Strength of Ca ²⁺ Binding to Retinal Lipid Membranes: Consequences for Lipid Organization", Biophys. J. 78, 3011-3018 (2000).	
	75	IGARASHI et al., "Agonist-Modulated Targeting of the EDG-1 Receptor to Plasmalemmal Caveolae", Journal of Biological Chemistry 2000;275(41):32363-70.	
	76	IMAIZUMI et al., "Effects of Dietary Sphingolipids on Levels of Serum and Liver Lipids in Rats", Nutr Res 1992;12:543-8.	
	77	INCARDONA et al., "Cholesterol in Signal Transduction", Curr Opin Cell Biol 2000;12(2):193-203.	
	78	ITOH et al., "Modified Bartlett Assay for Microscale Lipid Phosphorus Analysis", Anal Biochem 1986;154(1):200-4.	
	79	ITOH, et al., "Inorganic Phosphate Regulates the Contraction-Relaxation Cycle in Skinned Muscles of The Rabbit Mesenteric Artery", J. Physiol. - London 376, 231-252 (1986).	
	80	IWABUCHI et al., "Reconstitution of Membranes Simulating "Glycosignaling Domain" and Their Susceptibility ..", Journal of Biological Chemistry 2000;275(20):15174-81.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 10	of 21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	81	IWAMORI et al., "Gangliosides of Various Rat Tissues: Distribution of Ganglio-N-Tetraose-Containing Gangliosides ..", 1984. J. Biochem. 95:761-770.	
	82	IUPAC-IUB, Commission on Biochemical Nomenclature: "The Nomenclature of Lipids", Eur. J. Biochem. 79 (1977) 11-21.	
	83	JARROL et al., "Lipid and Carbohydrate Metabolism of Giardia Lamblia", 1981. Mol. Biochem. Parasitol. 2:187-196.	
	84	JENNNINGS et al., "The Significance of Lowered Jejunal Disaccharidase Levels", 1976. Aust. NZ J. Med. 6:556-560.	
	85	JUMPSSEN et al., "During Neuronal and Glial Cell Development Diet n - 6 to n - 3 Fatty Acid Ratio Alters the Fatty Acid Composition..", Biochim Biophys Acta 1997;1347(1):40-50.	
	86	KARLSSON et al., "Biochemical Development of Rat Forebrains in Severe Protein and Essential Fatty Acid Deficiencies", J Neurochem 1978;31:657-62.	
	87	KARLSSON, "Microbial Recognition of Target-Cell Glycoconjugates", 1995. Curr. Opin. Structur. Bio.5:622-635.	
	88	KASAHARA et al., "Possible Roles of Glycosphingolipids in Lipid Rafts", Biophysical Chemistry 1999;82(2-3):121-7.	
	89	KEENAN et al., "The Structure of Milk." In: Handbook of Milk Composition. Jensen RG, ed. Academic Press: New York, pp 5-85, 1995.	
	90	KEENAN et al., "Physical Equilibria: Lipid phase", In: Fundamentals of Dairy Chemistry, 3rd ed. Wong NP, ed. Van Nostrand Reinhold Company: New York, pp 511-582, 1988.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 11 of 21	Attorney Docket Number	D4858-00059	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	91	KATAGIRI et al., "Activation of Src Family Kinase Yes Induced by Shiga Toxin Binding to Globotriaosyl Ceramide..", Journal of Biological Chemistry 1999;274(49):35278-82.	
	92	KOBAYASHI et al., "A Long-Term Feeding of Sphingolipids Affected the Levels of Plasma Cholesterol and Hepatic Triacylglycerol..", Nutr Res 1997;17:111-4.	
	93	KOLDOVSKY, "Hormonally Active Peptides in Human Milk", Acta Paediatr Suppl 1994;402:89-93.	
	94	KOUMANOV et al., "Modulation of Human Type II Secretory Phospholipase A2 by Sphingomyelin and Annexin VI", Biochem J 1997;326 (Pt 1):227-33.	
	95	KRAJNC et al., "Neonatal Hypoxia; Early Neurotransmitter Responses and The Consequences of Treatment With GM1 Ganglioside", J Pharmacol Exp Ther 1994;271:1299-305.	
	96	KYOGASHIMA et al., "Escherichia coli K99 Binds to N-Glycolylsialoparagloboside and N-Glycolyl-GM3 Found in Piglet Small Intestine", 1989. Arch. Biochem. Biophys. 270:391-397.	
	97	LAEGREID et al., "Trace Amounts of Ganglioside GM1 in Human Mile Inhibit Enterotoxins From Vibrio Cholerae and Escherichia Coli", Life Sci 1987;40(1):55-62.	
	98	LAZZARO et al., "GM1 Reduces Infarct Volume After Focal Cerebral Ischemia", Exp Neurol 1994;125:278-85.	
	99	LEDEEN, "Biosynthesis, Metabolism, and Biological Effects of Gangliosides", Neurobiology of Glycoconjugates. New York: Plenum Press; 1989.	
	100	LEDEEN et al., "The Role of GM1 and Other Gangliosides in Neuronal Differentiation, Overview and New Finding", Ann. N. Y. Acad. Sci. 845 (1998) 161-175.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 12 of 21	Attorney Docket Number	D4858-00059	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	101	LEIKIN et al., "In Vivo Cholesterol Removal From Liver Microsomes Induces Changes in Fatty Acid Desaturase Activities", Biochim. Biophys. Acta 963 (1988) 311-319.	
	102	LENCER et al., "Targeting of Cholera Toxin and Escherichia coli Heat Labile Toxin in Polarized Epithelia", Journal of Cell Biology 1995;131(4):951-62.	
	103	LENCER et al., "Transcytosis of Cholera Toxin Subunits Across Model Human Intestinal Epithelia", Proc Natl Acad Sci USA 1995; 92:10094-8.	
	104	LERAY et al., "Molecular Species of Choline and Ethanolamine Phospholipids in Rat Cerebellum During Development", J. Neurochem. 54 (1990) 1677-1681.	
	105	LIU et al., "Compartmentalized Production of Ceramide at The Cell Surface", J Biol Chem 1995;270(45):27179-85.	
	106	MAJOUL et al., "Transport of an External Lys-Asp-Glu-Leu (SKEL) Protein from the Plasma Membrane to the Endoplasmic Reticulum", J Cell Biol 1996;133(4):777-89.	
	107	MAEKAWA et al., "Cholesterol-Dependent Localization of NAP-22 on a Neuronal Membrane Microdomain (Raft)", J Biol Chem 1999;274:21369-74.	
	108	MALEWICZ et al., "Lipids in Gap Junction Assembly and Function", Lipids 1990;25:419-27.	
	109	MALISAN et al., "GD3 Ganglioside and Apoptosis", Biochim. Biophys. Acta 1585 (2002) 179-187.	
	110	MATHER. "Proteins of the Milk-Fat Globule Membrane as Markers of Mammary Epithelial Cells..", Neville MC, Daniel CW, eds. Plenum Press: New York, pp 217-267, 1987.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/551,789
				Filing Date	07-05-2006
				First Named Inventor	Michael Thomas Clandinin
				Art Unit	1623
				Examiner Name	Eric Olson
Sheet	13	of	21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	111	MAVROMOUSTAKOS et al., "Ether Phospholipid-AZT Conjugates Possessing Anti-HIV and Antitumor Cell Activity.", J. Med. Chem. 44 (2001) 1702-1709.	
	112	MERRILL et al., "Sphingolipids – The Enigmatic Lipid Class: Biochemistry, Physiology, and Pathophysiology", Toxicol. Appl. Pharmacol. 142 (1997) 208-225.	
	113	MENDEZ-OTERO et al., "Functional Role of a Specific Ganglioside in Neuronal Migration and Neurite Outgrowth", Braz. J. Med. Biol. Res. 36, 1003-1013 (2003).	
	114	MERRILL et al., "Sphingolipid Biosynthesis de Novo by Rat Hepatocytes in Culture", J. Biol. Chem. 270 (1995) 13834-13841.	
	115	MOHAND-SAID et al., "Intravitreal Injection of Ganglioside GM1 After Ischemia Reduces Retinal Damage in Rats", Stroke 28 (1997) 617-621.	
	116	MORAN et al., "Engagement of GPI-Linked CD48 Contributes to TCR Signals and Cytoskeletal Reorganization: A Role for ..", Immunity 1998;9:787-796.	
	117	MORGAN et al., "Effects of Administration of N-Acetylneuraminic Acid (NANA) on Brain NANA Content and Behavior", J Nutr 1980;110:416-24.	
	118	MOXEY et al., "Development of Villus Absorptive Cells in the Human Fetal Small Intestine: A Morphological and Morphometric Study", Anatomical Record 1979;195(3):462-83.	
	119	MURPHY et al., "Effects of Differentiation on the Phospholipid and Phospholipid Fatty Acid Composition ..", Biochim. Biophys. Acta 1167 (1993) 131-136.	
	120	NILSSON, "Metabolism of Sphingomyelin In the Intestinal Tract of the Rat", Biochim. Biophys. Acta 164 (1968) 575-584.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 14 of 21	Attorney Docket Number	D4858-00059	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	121	NISHIZAWA et al., "Effect of Dietary DHA on DHA Levels in Retinal Rod Outer Segments in Young Versus Mature Rats", Int. J. Vitam. Nutr. Res. 73, 259-265 (2003).	
	122	NIXON et al., "Comparison of Alkylacylglycerol vs. Diacylglycerol as Activators of Mitogen-Activated Protein Kinase ..", Biochim. Biophys. Acta 1347 (1997) 219-230.	
	123	OGURA et al., "Metabolism of Exogenous Gangliosides GM1 and Chemically Modified GM1 in Mice", J. Biochem. 104 (1988) 87-92.	
	124	OISHI et al., "Inhibition of Na, K-ATPase and Sodium Pump by Anticancer Ether Lipids and Protein Kinase C Inhibitors...", Biochem. Biophys. Res. Commun. 157 (1988) 1000-1006.	
	125	OKAYASU et al., "Platelet-Activating Factor Stimulates Metabolism of Phosphoinositides via Phospholipase A2 in Primary ..", J Lipid Res 1987;28(7):760-7.	
	126	ORTALDO et al., "T Cell Activation via the Disialoganglioside GD3: Analysis of Signal Transduction", Journal of Leukocyte Biology 1996;60(4):533-9.	
	127	ORTEGA et al., "Cholesterol Effect on Enzyme Activity of the Sarcolemmal (Ca ²⁺ + Mg ²⁺) - ATPase From Cardiac Muscle", Biochim Biophys Acta 1984;773:231-6.	
	128	ORTEGA-BARRIA et al., "Growth Inhibition of the Intestinal Parasite Giardia Lamblia by a Dietary Lectin is Associated with Arrest of the Cell Cycle", 1994. J. Exp. Med. 94:228	
	129	PALTAUF, "Ether Lipids in Biomembranes", Chem. Phys. Lipids 74 (1994) 101-139.	
	130	PALTAUF, "Intestinal Uptake and Metabolism of Alkyl Acyl Glycero Phospholipids and of Alkyl Glycerophospholipids in the Rat", Biochim. Biophys. Acta 260 (1972) 352-364.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/551,789
				Filing Date	07-05-2006
				First Named Inventor	Michael Thomas Clandinin
				Art Unit	1623
				Examiner Name	Eric Olson
Sheet	15	of	21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	131	PAN et al., "Variation of the Ganglioside Compositions of Human Milk, Cow's Milk and Infant Formulas", Early Hum Dev 2000;57:25-31.	
	132	PARKER et al., "Evidence of Protein Kinase C Involvement in Phorbol Diester-Stimulated Arachidonic Acid Release ..", J. Biol. Chem. 262 (1987) 5385-5393.	
	133	PARPAL et al., "Cholesterol Depletion Disrupts Caveolae and Insulin Receptor Signaling for Metabolic Control Via Insulin Receptor Substrate-1..", J Biol Chem 2001;276:9670-8.	
	134	PARTON, "Ultrastructural Localization of Gangliosides; GM1 Is Concentrated in Caveolae", J Histochem Cytochem 1994;42:155-66.	
	135	PATTON et al. "The Milk Fat Globule Membrane", Biochim Biophys Acta 415:273-309, 1975.	
	136	PERKKIO et al., "Time of Appearance of Immunoglobulin-Containing Cells in the Mucosa of the Neonatal Intestine", Pediatr Res 1980;14:953-5.	
	137	POLIT et al., "Effects of Docosahexaenoic Acid on Retinal Development: Cellular and Molecular Aspects", Lipids 36 (2001) 927-935.	
	138	POPIK et al., "Human Immunodeficiency Virus Type 1 Uses Lipid Raft-Colocalized CD4 and Chemokine Receptors for Productive..", J Virol 2002;76(10):4709-22.	
	139	PRINCIPE et al., "Flow Cytometric Monitoring of Anthracycline Accumulation After Anti-Neoplastic Ether Phospholipid Treatment", Anticancer Drugs 5 (1994) 329-335.	
	140	PRINETTI et al., "Glycosphingolipid-Enriched Signaling Domain in Mouse Neuroblastoma Neuro2a Cells", Journal of Biological Chemistry 1999;274(30):20916-24.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/551,789
				Filing Date	07-05-2006
				First Named Inventor	Michael Thomas Clandinin
				Art Unit	1623
				Examiner Name	Eric Olson
Sheet	16	of	21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	141	PRESCOTT et al., "Platelet-Activating Factor", J Biol Chem 1990;265 (29):17381-4.	
	142	RECORD et al., "Evidence for a Highly Asymmetric Arrangement of Ether- and Diacyl-Phospholipid Subclasses in the Plasma..", Biochim. Biophys. Acta 778 (1984) 449-456.	
	143	REINER et al., "Human Milk Kills Giardia Lamblia by Generating Toxic Lipolytic Products", 1986. J. Infect. Dis. 154:825-832.	
	144	REISS et al., "Delayed Oxidative Degradation of Polyunsaturated Diacyl Phospholipids in the Presence of Plasmalogen Phospholipids in vitro", Biochem. J. 323 (1997) 807-814.	
	145	RIETVELD et al., "The Differential Miscibility of Lipids as the Basis for the Formation of Functional Membrane Rafts:", Biochim Biophys Acta 1998;1376:467-79.	
	146	ROBERTS-THOMSON et al., "Giardiasis in the Mouse: An Animal Model", 1976. Gastroenterology. 71:57-61.	
	147	ROHRER et al., "Killing of Giardia Lamblia by Human Milk is Mediated by Unsaturated Fatty Acids", 1986. Antimicrob. Agents Chemother. 30:254-257.	
	148	ROLSMA et al., "Structure and Function of a Ganglioside Receptor for Porcine Rotavirus", Journal of Virology 1998;72(11):9079-91.	
	149	ROUSER et al., "Curvilinear Regression Course of Human Brain Lipid Composition Changes With Age", Lipids 3 (1968) 284-287.	
	150	RUEDA et al., "Changes During Lactation in Ganglioside Distribution in Human Milk from Mothers Delivering Preterm and Term Infants", 1996. Biol. Chem. 377:599-601.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/551,789
				Filing Date	07-05-2006
				First Named Inventor	Michael Thomas Clandinin
				Art Unit	1623
				Examiner Name	Eric Olson
Sheet	17	of	21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	151	RUEDA et al., "Addition of Gangliosides to an Adapted Milk Formula Modifies Levels of Fecal Escherichia coli in Preterm Newborn Infants", 1998a. J. Pediatr. 133:90-94.	
	152	RUEDA et al., "Neonatal Dietary Gangliosides", Early Human Development 1998b;53:S135-S147.	
	153	SAMUEL et al. "The Role of Cholesterol and Glycosylphosphatidylinositol-Anchored Proteins of Erythrocyte Rafts in Regulating ..", J Biol Chem 2001;276:29319-29.	
	154	SANCHEZ-DIAZ et al., "A Critical Analysis of Total Sialic Acid and Sialoglycoconjugate Contents of Bovine..", J Pediatr Gastroenterol Nutr 1997;24:405-410.	
	155	SCHMELZ et al., "Uptake and Metabolism of Sphingolipids in Isolated Intestinal Loops of Mice", J. Nutr. 124 (1994) 702-712.	
	156	SCHMELZ et al., "Colonic Cell Proliferation and Aberrant Crypt Foci Formation Are Inhibited by Dairy Glycosphingolipids in ..", J. Nutr. 130 (2000) 522-527.	
	157	SCIORRA et al., "Sequential Actions of Phospholipase D and Phosphatidic Acid Phosphohydrolase 2b Generate ..", Molecular Biology of the Cell 1999;10(11):3863-76.	
	158	SEEWALD et al., "Inhibition of Growth Factor-Dependent Inositol Phosphate Ca ²⁺ Signaling by Antitumor Ether Lipid Analogues", Cancer Res. 50 (1990) 4458-4463.	
	159	SENN et al., "Gangliosides in Normal Human Serum", Eur J Biochem 1989;181:657-62.	
	160	SEYFRIED, et al., "Gangliosides Gp3: Structure, Cellular Distribution, and Possible Function", Mol. Cell Biochem. 68, 3-10 (1985).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 18 of 21	Attorney Docket Number	D4858-00059	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	161	SIMONS et al., "Functional Rafts in Cell Membranes", Nature 1997;387 (6633):569-72.	
	162	SINDELAR et al., "The Protective Role of Plasmalogens in Iron-Induced Lipid Peroxidation", Free Radic. Biol. Med. 26 (1999) 318-324.	
	163	SLOTTE, "Sphingomyelin-Cholesterol Interactions in Biological and Model Membranes", Chem Phys Lipids 1999;102:13-27.	
	164	SMART et al., "Hormonal Regulation of Caveolae Internalization", Journal of Cell Biology 1995;131(4):929-38.	
	165	SMART et al., "The Caveolae Internalization Cycle: Regulation by PKC α -Mediated Phosphorylation of a 90-kDa Protein", Molecular Biology of the Cell 1995;6:778.	
	166	SONNINO et al., "Recognition by Two-Dimensional Thin-Layer Chromatography and Densitometric Quantification of Alkali-Labile..", Anal Biochem 1983;128:104-14.	
	167	SORICE et al., "Evidence for the Existence of Ganglioside Molecules in the Antigen of Entamoeba Histolytica", 1996. Parasite Immunol. 18:133-137.	
	168	STAUFFER et al., "Compartmentalized IgE Receptor-Mediated Signal Transduction in Living Cells", J Cell Biol 1997;139:1447-54.	
	169	STEVENS et al., "Uptake and Cellular Localization of Exogenous Lipids by Giardia Lamblia, a Primitive Eukaryote", 1997. Exp. Parasitol. 86:133-143.	
	170	STULNIG et al., "Polyunsaturated Eicosapentaenoic Acid Displaces Proteins From Membrane Rafts by ..", Journal of Biological Chemistry 2001;276(40):37335-40.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,789
		Filing Date	07-05-2006
		First Named Inventor	Michael Thomas Clandinin
		Art Unit	1623
		Examiner Name	Eric Olson
Sheet 19 of 21	Attorney Docket Number		D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	171	SUZUKI, "A Simple and Accurate Micromethod for Quantitive Determination of Ganglioside Patterns", 1964. Life Sci. 3:1227-1233.	
	172	SUH, WIERZBICKI, AND CLANDININ, "Dietary Fat Alters Membrane Composition in Rod Outer Segments in Normal and Diabetic Rats..", BBA-Lipid Lipid Met. 1214, 54-62 (1994).	
	173	SUN et al., "Age Changes in the Lipid Composition of Whole Homogenates and Isolated Myelin Fractions of Mouse Brain", J Gerontol 1972;27:10-17.	
	174	SVENNERHOLM, "Quantitative Estimation of Sialic Acids", Biochimica et Biophysica Acta 1957;24:604-11.	
	175	SVENNERHOLM, "Chromatographic Separation of Human Brain Gangliosides", J. Neurochem. 10 (1963) 613-623.	
	176	SVENNERHOLM, "The Gangliosides", Journal of Lipid Research 1964;5:145-55.	
	177	SVENNERHOLM et al., "Human Brain Gangliosides: Developmental Changes from Early Fetal Stage to Advanced Age", Biochim. Biophys. Acta 1005 (1989) 109-117.	
	178	TAKAMIZAWA et al., "Selective Changes in Gangliosides of Human Milk During Lactation", Biochim Biophys Acta 1986;879:73-7.	
	179	THOMPSON et al., "Inhibition of the Adherence of Cholera Toxin and the Heat-Labile Enterotoxin of Escherichia coli to..", Biochem. Pharmacol. 56 (1998) 591-597.	
	180	TRIANTAFILOU et al., "Mediators of Innate Immune Recognition of Bacteria Concentrate in Lipid Rafts and Facilitate..", J Cell Sci 2002;115(Pt 12):2603-11.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/551,789
				Filing Date	07-05-2006
				First Named Inventor	Michael Thomas Clandinin
				Art Unit	1623
				Examiner Name	Eric Olson
Sheet 20	of 21	Attorney Docket Number		D4858-00059	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	181	UNDERDOWN et al., "Giardiasis in Mice: Studies on the Characteristics of Chronic Infection in C3H/He Mice", 1981. J. Immunol.; 126:669-672.	
	182	VANIER et al., "Developmental Profiles of Gangliosides in Human and Rat Brain", J Neurochem 1971;18:581-92.	
	183	VAZQUEZ et al. "Dietary Gangliosides Positively Modulate the Percentages of Th1 and Th2 Lymphocyte Subsets in Small Intestine of Mice at Weaning", Biofactors 15 (2001) 1-9.	
	184	VESPER et al., "Sphingolipids in Food and the Emerging Importance of Sphingolipids to Nutrition", J. Nutr. 129 (1999) 1239-1250.	
	185	WALTERSPIEL et al., "Secretory Anti-Giardia Lamblia Antibodies in Human Milk: Protective Effects Against Diarrhea", 1994. Pediatrics. 93:28-31.	
	186	WATARAI et al., "Gangliosides as a Possible Receptor on the Bovine Erythrocytes for Theileria sergenti", 1995. J. Vet. Med. Sci. 57:17-22.	
	187	WELTE et al., "Stimulation of T Lymphocyte Proliferation by Monoclonal Antibodies Against Gp3 Ganglioside", J Immunol 1987;139:1763-71.	
	188	WILLIAMS et al., "The Use of Sep-Pak C18 Cartridges During the Isolation of Gangliosides", Journal of Neurochemistry 1980;35(1):266-9.	
	189	WILLIAMS et al., "Docosahexaenoic Acid (DHA) Alters the Phospholipid Molecular Species Composition ..", Biochimica et Biophysica Acta-Biomembranes 1999;1418(1):185-96.	
	190	WILSON et al., "Biogenesis of the Apical Endosome-Lysosome Complex During Differentiation of Absorptive Epithelial..", Journal of Cell Science 1991;100:133-43.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/551,789
				Filing Date	07-05-2006
				First Named Inventor	Michael Thomas Clandinin
				Art Unit	1623
				Examiner Name	Eric Olson
Sheet	21	of	21	Attorney Docket Number	D4858-00059

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	191	WOLF et al., "Uncoupling of the Cholera Toxin-GM1 Ganglioside Receptor Complex Form Endocytosis,...", Journal of Biological Chemistry 2002;277(18):16249-56.	
	192	WOLFE "Giardiasis", 1992. Clin. Microbiol. Rev. 5:93-100.	
	193	XI et al., "Effect of Dietary n-3 Fatty Acids on the Composition of Long- and Very-Long-Chain Polyenoic Fatty Acid in Rat Retina", J. Nutr. Sci. Vitaminol. 49, 210-213 (2003).	
	194	YAMAMURA et al., "A Close Association of GM3 with c-Src and Rho in GM3-Enriched Microdomains at the B16 Melanoma..", Biochem Biophys Res Commun 1997;236(1):218-22.	
	195	ZHENG et al., "Inhibition of Protein Kinase C, (Sodium plus Potassium)-Activated Adenosine Triphosphatase, and Sodium Pump..", Cancer Res. 50 (1990) 3025-3031.	
	196	International Search Report for Corresponding PCT App. No. PCT/CA2004/000375 dated November 10, 2004	
	197	BUCOLO et al., "Effects of Mipragoside on Ocular Allergic Inflammation in the Rabbit" J. of Ocular Pharmacology, Mary Liebert, New York, vol. 9, No. 4, 1993, 321-332, Abstract	
	198	OLIVEIRA, et al., "GM-1 Ganglioside Treatment Reduces Motoneuron Death After Ventral Root Avulsion in Adult Rats", Neuroscience Letters, vol. 293, No. 2, 10/27/2000, 131-134	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.